Study: NCT04488016

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A- Part 1
Description: Subjects will receive 100 mg acalabrutinib capsule, fasted state;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A- Part 1
Description: Subjects will receive 100 mg acalabrutinib capsule, fasted state;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A- Part 1
Description: Subjects will receive 100 mg acalabrutinib capsule, fasted state;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A- Part 1
Description: Subjects will receive 100 mg acalabrutinib capsule, fasted state;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B- Part 1
Description: Subjects will receive 100 mg acalabrutinib tablet (Variant 1), fasted state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B- Part 1
Description: Subjects will receive 100 mg acalabrutinib tablet (Variant 1), fasted state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B- Part 1
Description: Subjects will receive 100 mg acalabrutinib tablet (Variant 1), fasted state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B- Part 1
Description: Subjects will receive 100 mg acalabrutinib tablet (Variant 1), fasted state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C - Part 1
Description: Subjects will receive 100 mg acalabrutinib tablet (Variant 1), fed state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C - Part 1
Description: Subjects will receive 100 mg acalabrutinib tablet (Variant 1), fed state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C - Part 1
Description: Subjects will receive 100 mg acalabrutinib tablet (Variant 1), fed state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C - Part 1
Description: Subjects will receive 100 mg acalabrutinib tablet (Variant 1), fed state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment D- Part 1
Description: Subjects will receive Rabeprazole 20 mg QD (fasted) at 2 hours before administration of 100 mg acalabrutinib tablet (Variant 1) and following prior administration of rabeprazole 20 mg Twice per day (BID) (with meals) on Days -3, -2 and -1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment D- Part 1
Description: Subjects will receive Rabeprazole 20 mg QD (fasted) at 2 hours before administration of 100 mg acalabrutinib tablet (Variant 1) and following prior administration of rabeprazole 20 mg Twice per day (BID) (with meals) on Days -3, -2 and -1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A-Part 2
Description: Subjects will receive 100 mg acalabrutinib tablet (Variant 1), fasted state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A-Part 2
Description: Subjects will receive 100 mg acalabrutinib tablet (Variant 1), fasted state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B - Part 2
Description: Subjects will receive 100 mg acalabrutinib tablet (Variant 2), fasted state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B - Part 2
Description: Subjects will receive 100 mg acalabrutinib tablet (Variant 2), fasted state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C - Part 2
Description: Subjects will receive 100 mg acalabrutinib tablet (Variant 3), fasted state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C - Part 2
Description: Subjects will receive 100 mg acalabrutinib tablet (Variant 3), fasted state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment D - Part 2
Description: Subjects will receive 100 mg acalabrutinib solution, (Variant 4), fasted state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment D - Part 2
Description: Subjects will receive 100 mg acalabrutinib solution, (Variant 4), fasted state